Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
87
datasets available to search
ShareScore release 0.9.0
Dataset results
87 results for “indacaterol”
Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)
ClinicalTrials.gov study NCT02473237. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Data from: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
Purpose: In the absence of head-to-head clinical trials comparing the once-daily, long-acting beta2-agonists olodaterol and indacaterol for the treatment of chronic obstructive pulmonary disease (COPD), an indirect treatment comparison by systematic review and synthesis of the available clinical evidence was conducted. Methods: A systematic literature review of randomized, controlled clinical trials in patients with COPD was performed to evaluate the efficacy and safety of olodaterol and indacaterol. Network meta-analysis and adjusted indirect comparison methods were employed to evaluate treatment efficacy, using outcomes based on trough forced expiratory volume in 1 second (FEV1), Transition Dyspnea Index, St George's Respiratory Questionnaire total score and response, rescue medication use, and proportion of patients with exacerbations. Results: Eighteen trials were identified for meta-analysis (eight, olodaterol; ten, indacaterol). Olodaterol trials included patients of all severities, whilst indacaterol trials excluded patients with very severe COPD. Concomitant maintenance bronchodilator use was allowed in most olodaterol trials, but not in indacaterol trials. When similarly designed trials/data were analyzed for change from baseline in trough FEV1 (liters), the following mean differences (95% confidence interval) were observed: trials excluding concomitant bronchodilator: indacaterol 75 mcg versus olodaterol 5 mcg, –0.005 (–0.077 to 0.067), and indacaterol 150 mcg versus olodaterol 5 mcg, 0.020 (–0.036 to 0.077); trials with concomitant tiotropium: indacaterol 150 mcg versus olodaterol 5 mcg, 0.000 (–0.043 to 0.042). In sensitivity analyses of the full network, results for change from baseline in trough FEV1 favored indacaterol, but this dataset suffered from trial design heterogeneity. For the other endpoints investigated, no statistically significant differences were found when analyzed in the full network. Conclusion: When compared under similar trial conditions, olodaterol and indacaterol have similar efficacy in patients with COPD. This research highlights the importance of considering the concomitant COPD medication when evaluating treatment effects in COPD.
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
ClinicalTrials.gov study NCT01609478. IPD Sharing: Not stated. Countries: 8. Publications: 0.
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
ClinicalTrials.gov study NCT00605306. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT00669617. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)
ClinicalTrials.gov study NCT01555138. IPD Sharing: Not stated. Countries: 9. Publications: 0.
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
ClinicalTrials.gov study NCT05562466. IPD Sharing: YES. Countries: 16. Publications: 0.
Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT01543828. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
ClinicalTrials.gov study NCT00529529. IPD Sharing: Not stated. Countries: 12. Publications: 0.
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT01089127. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT00622635. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Efficacy and Safety of Different Doses of Indacaterol
ClinicalTrials.gov study NCT01079130. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
ClinicalTrials.gov study NCT00531050. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
ClinicalTrials.gov study NCT00545272. IPD Sharing: Not stated. Countries: 10. Publications: 0.
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
ClinicalTrials.gov study NCT01232894. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With C
ClinicalTrials.gov study NCT00636961. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dose Ranging Study for Indacaterol in Japanese Asthma Patients
ClinicalTrials.gov study NCT00403754. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
ClinicalTrials.gov study NCT02418468. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device
ClinicalTrials.gov study NCT01484197. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
ClinicalTrials.gov study NCT01959412. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.